Research Article
Correlates of Nine-Month Retention following Interim Buprenorphine-Naloxone Treatment in Opioid Dependence: A Pilot Study
Table 1
Characteristics of subjects with and without 9-month retention in OMT after transition from buprenorphine interim phase.
| | | Total | Retention
> 9 months | Retention
< 9 months | |
| | Number of patients | 36 | 30 | 6 | | | Age, median (IQR) | 33 (29–42) | 32 (29–42) | 35 (30–50) | 0.419 | | Male, % () | 89% (32) | 90% (27) | 83% (5) | 0.635 | | Born in Sweden, % () | 86% (31) | 83% (25) | 100% (6) | 0.281 | | Previous overdose, % () | 69% (24) | 66% (19) | 83% (5) | 0.392 | | Previous attempt to commit suicide, % () | 31% (11) | 31% (9) | 33% (2) | 0.912 | | Days spent in interim phase, median (IQR) | 35 (24–50) | 35 (25–50) | 31 (20–55) | 0.756 | | Substance use in past 30 days, % () | | | | | | Heroin | 72% (26) | 70% (21) | 83% (5) | 0.506 | | Methadone | 53% (19) | 50% (15) | 67% (4) | 0.455 | | Buprenorphine | 75% (27) | 77% (23) | 67% (4) | 0.606 | | Buprenorphine-naloxone | 25% (9) | 27% (8) | 17% (1) | 0.606 | | Benzodiazepines | 69% (25) | 67% (20) | 83% (5) | 0.418 | | Cannabis | 53% (19) | 53% (16) | 50% (3) | 0.881 | | Amphetamine | 36% (13) | 27% (11) | 33% (2) | 0.877 | | Cocaine | 6% (2) | 7% (2) | 0% (0) | 0.515 | | Number of days of substance use in past 30 days, (IQR) | | | | | | Heroin | 3 (0–13) | 3 (0–13) | 7 (2–17) | 0.519 | | Methadone | 1 (0–4) | 1 (0–3) | 1 (0–17) | 0.514 | | Buprenorphine | 11 (1–27) | 11 (1–26) | 11 (0–28) | 0.915 | | Buprenorphine-naloxone | 0 (0-1) | 0 (0-1) | 0 (0–3) | 0.696 | | Benzodiazepines | 4 (0–14) | 4 (0–16) | 6 (2–15) | 0.517 | | Cannabis | 2 (0–9) | 2 (0–8) | 1 (0–10) | 0.689 | | Amphetamine | 0 (0-1) | 0 (0-1) | 0 (0–3) | 0.901 | | Cocaine | 0 (0-0) | 0 (0-0) | — | 0.521 | | AUDIT, hazardous use, % () | 31% (11) | 30% (9) | 33% (2) | 0.871 | | AUDIT score, median (IQR) | 5 (1–10) | 5 (1–11) | 4 (1–14) | 0.881 |
|
|
